Mohan V, Bruin N M, van de Kamer J B, Sonke J-J, Vogel W V
Department of Nuclear Medicine, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
EJNMMI Res. 2021 Sep 26;11(1):95. doi: 10.1186/s13550-021-00838-y.
PSMA-directed therapy for metastatic prostate cancer is gaining adoption as a treatment option. However, accumulation of Lu/Ac-PSMA in the salivary glands remains a problem, with risk of dose-limiting xerostomia and potentially severe effect on the quality of life. Gustatory stimulation is an approach that has commonly been used in radioactive iodine therapy to reduce accumulation in the salivary glands. However, based on theoretical differences in biodistribution, it was hypothesized that this could potentially lead to adverse increased toxicity for PSMA-ligand therapy. The primary objective of this work was to determine if gustatory stimulation by eating an assortment of sweet/fatty/acidic foods during the biodistribution phase of [F]DCFPyl could result in a clinically relevant (> 30%) change in the uptake of the tracer in the salivary glands.
10 patients who already received a whole-body [F]DCFPyl PET/CT scan for evaluation of prostate cancer, underwent a repeat (intervention) PET/CT scan within a month of the first (control) scan. During the intervention scan, patients chose from an assortment of sweet/fatty/acidic foods, which they then chewed and swallowed for a period of time starting 1 min before tracer administration to 10 min thereafter. Data from both scans were analyzed by placing VOIs on the major salivary glands and segmenting them using relative thresholds.
A slight increase in PSMA uptake in the parotid glands was observed on the intervention scan when compared to the baseline scan (+ 7.1% SUL and + 9.2% SUL, p < 0.05). No significant difference in PSMA uptake in the submandibular glands was seen.
Eating only slightly increases uptake of [F]DCFPyl in the parotid glands. We nonetheless recommend refraining from gustatory stimulation during the administration and early biodistribution phase of radionuclide therapy with PSMA-ligands to reduce the risk of avoidable additional toxicity.
针对转移性前列腺癌的PSMA导向治疗正逐渐成为一种治疗选择。然而,镥/锕-PSMA在唾液腺中的蓄积仍然是一个问题,存在剂量限制的口干风险,并可能对生活质量产生严重影响。味觉刺激是放射性碘治疗中常用的一种方法,用于减少唾液腺中的蓄积。然而,基于生物分布的理论差异,有人推测这可能会导致PSMA配体治疗的毒性增加。这项工作的主要目的是确定在[F]DCFPyl生物分布阶段食用各种甜/脂肪/酸性食物进行味觉刺激是否会导致示踪剂在唾液腺中的摄取发生临床相关(>30%)变化。
10名已接受全身[F]DCFPyl PET/CT扫描以评估前列腺癌的患者,在首次(对照)扫描后的一个月内接受了重复(干预)PET/CT扫描。在干预扫描期间,患者从各种甜/脂肪/酸性食物中进行选择,然后在示踪剂给药前1分钟至给药后10分钟期间咀嚼并吞咽一段时间。通过在主要唾液腺上放置感兴趣区(VOI)并使用相对阈值对其进行分割,分析两次扫描的数据。
与基线扫描相比,干预扫描时腮腺中PSMA摄取略有增加(标准化摄取值[SUL]增加7.1%和9.2%,p<0.05)。颌下腺中PSMA摄取未见显著差异。
进食仅使腮腺中[F]DCFPyl的摄取略有增加。尽管如此,我们建议在使用PSMA配体进行放射性核素治疗的给药和早期生物分布阶段避免味觉刺激,以降低可避免的额外毒性风险。